Collaboration, License and Other Arrangements - Schedule of Credits Recognized in Condensed Consolidated Statements of Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of sales	$ 414.8	$ 392.6	$ 1,185.3	$ 1,107.1
Research and development expenses	977.7	875.9	2,935.8	2,631.6
Acquired in-process research and development expenses	54.5	15.0	76.5	4,540.9
CRISPR JDCA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of sales	43.3	15.8	109.6	47.5
Research and development expenses	14.3	11.7	45.4	35.0
Acquired in-process research and development expenses	$ 0.0	$ 0.0	$ 12.5	$ 0.0